Hepatocellular (HCC) is the most common type of primary liver cancer and the fourth most common cause of cancer-related deaths globally.1 Although most cases of HCC were historically attributed to underlying chronic viral hepatitis, nonalcoholic fatty liver disease is projected to become the most common risk factor for HCC with the rising prevalence of obesity and diabetes mellitus and increasing availability of effective treatments for hepatitis B and C infection.2 Although patients with viral and nonviral HCC seem to have similar overall prognosis,3 prior data have suggested possible differential efficacy of systemic therapies by liver disease etiology. For example, sorafenib was shown to have greater efficacy in patients with chronic hepatitis C infection than other etiologies.4 The aim of our descriptive study was to report the effectiveness of lenvatinib in a real-world cohort of patients with nonalcoholic steatohepatitis (NASH)-related HCC.

中文翻译：

---

Lenvatinib 在患有非酒精性脂肪性肝炎的肝细胞癌患者中的真实世界有效性。

肝细胞 (HCC) 是最常见的原发性肝癌类型，也是全球癌症相关死亡的第四大常见原因。 1 尽管大多数 HCC 病例在历史上都归因于潜在的慢性病毒性肝炎，但预计非酒精性脂肪性肝病将成为随着肥胖和糖尿病患病率的上升以及乙型和丙型肝炎感染有效治疗方法的增加，HCC 最常见的危险因素。 2 尽管病毒性和非病毒性 HCC 患者的总体预后似乎相似，3 之前的数据表明可能存在差异肝病病因系统治疗的疗效。例如，索拉非尼被证明对慢性丙型肝炎感染患者的疗效优于其他病因。